Skip to main content
. 2021 Aug 3;12:623777. doi: 10.3389/fneur.2021.623777

Table 1.

Patients' clinical and radiological features.

EpAD
(n = 29)
NepAD
(n = 38)
Statistics (p-value)
Female (n, %) 12 (41.4) 19 (50) 0.5a
Education, years (mean ± SD) 11.6 (±2.8) 11.1 (±2.5) 0.4b
Age at onset of cognitive decline, years (mean ± SD) 69.4 (±9.9) 64.3 (±7.2) 0.003b
EOAD/LOAD (n, %) 5 (17.2)/24 (82.8) 13 (34.2)/25 (65.8) 0.12a
Age at diagnosis of prodromal AD, years (mean ± SD) 72.8 (±8.7) 67.5 (±7.4) 0.001b
MMSE at baseline (/30) 26 (±2.4) 26.3 (±2.1) 0.5b
Family history of degenerative diseases (n, %) 11 (37.9) 22 (57.9) 0.1a
Hypertension (n, %) 17 (58.6) 11 (28.95) 0.01a
Dyslipidemia (n, %) 17 (58.6) 15 (39.5) 0.1a
Diabetes (n, %) 6 (20.7) 5 (13.2) 0.4a
Smoking (n, %) 12 (41.4) 17 (44.7) 0.8a
Alcohol (n, %) 2 (6.9) 3 (7.9) 0.9a
Imaging features
Hippocampal atrophy right (mean ± SD) 1.2 (±0.8) 1.2 (±1.0) 0.8b
Hippocampal atrophy left (mean ± SD) 1.2 (±0.9) 1.3 (±0.9) 1.0b
Subcortical lacunes (n, %) 5 (17.2) 3 (7.9) 0.2c
Subcortical microbleeds (n, %) 4 (14.8) 5 (14.7) 1.0c
Fazekas score (mean ± SD) 1.4 (±0.9) 0.95 (0.7) 0.05b
ChEI at AD diagnosis (n, %) 0 (0.0) 0 (0.0)

EOAD, early-onset Alzheimer's disease; LOAD, late-onset Alzheimer's disease; a, Chi-square test; b, Mann–Whitney test; c, Fischer's exact test; d, Student's test; ChEI, Cholinesterase inhibitors.

Significantly different values between epADs and nepADs appear in bold.